Detalles de la búsqueda
1.
Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
Ann Hematol
; 101(12): 2711-2717, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36271935
2.
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
Br J Haematol
; 192(6): 978-987, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862447
3.
Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
Hematol Oncol
; 39(2): 231-242, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33332639
4.
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Hematol Oncol
; 38(4): 541-553, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32495951
5.
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Ann Hematol
; 98(6): 1383-1392, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30877373
6.
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Hematol Oncol
; 36(4): 693-700, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30129144
7.
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Am J Hematol
; 93(7): 895-901, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29659040
8.
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.
Am J Hematol
; 98(5): E119-E122, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36808739
9.
A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births.
Ann Hematol
; 91(9): 1451-8, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22526366
10.
Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study.
Ther Adv Hematol
; 13: 20406207221090150, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35646300
11.
Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.
Leuk Lymphoma
; 63(3): 729-737, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34738857
12.
Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome.
Sci Rep
; 12(1): 17914, 2022 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36289284
13.
Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine.
Blood Adv
; 5(1): 129-142, 2021 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33570632
14.
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Lancet Haematol
; 8(2): e135-e148, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33513373
15.
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Haematologica
; 95(3): 406-14, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19773257
16.
Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up.
Am J Hematol
; 85(11): 894-6, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20872550
17.
Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study.
EJHaem
; 1(1): 255-261, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35847690
18.
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Ther Adv Hematol
; 11: 2040620720966121, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33343854
19.
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.
Clin Lymphoma Myeloma Leuk
; 20(2): 114-121, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31884152
20.
Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ.
Blood Adv
; 8(2): 399-402, 2024 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38011610